Approximately 10% of breast cancers are ER/PR+ HER2+, 69% are ER/PR+ HER2−, 7% are ER/PR− HER2+, and the remaining 13% are classified as triple-negative (TN) [1]. This evidence concerns the gene ESR1 and breast carcinoma.